Celiac Disease Market Assessment: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access

Table of Contents

• A life-altering autoimmune disease in genetically pre-disposed individuals
• Figure 1.1. Symptomatic presentations of CeD
• Figure 1.2. Villous atrophy in CeD
• Gluten digestion and the ensuing immune response offer numerous targets for drug development
• Figure 1.3. Gluten activation of the immune system and druggable targets

• Disease definition
• Figure 2.1. G6 diagnosed prevalent cases of CeD by region
• Table 2.1. Diagnosed prevalent and drug-treated CeD patients in the G6
• The CeD patient population is segmented into three distinct sub-populations
• Overview
• Table 2.2. Description of CeD patient segments
• Figure 2.2. Representation of CeD patient population segments

• Diagnosis overview
• Figure 3.1. Diagnostic pathway for CeD patients
• A gluten-free diet is the current standard of care for CeD
• Figure 3.2. Treatment goals for CeD
• Figure 3.3. Treatment rate among CeD patients
• Figure 3.4. Budesonide and azathioprine patient share in NRCD patients
• Treatment flow for CeD
• Figure 3.5. Treatment algorithm for CeD
• CeD diagnosis and treatment dynamics
• Figure 3.6 Gastroenterologist statement agreement on CeD diagnosis and treatment dynamics
• There is room for improvement over existing treatments
• Table 3.1. Upsides and downsides of current CeD treatments
• Key dynamics that shape treatment and disease management in CeD
• Table 3.2 Must-know CeD treatment dynamics
• The CeD market is poised to solidify with the first drug approval as early as 2025/2026
• Figure 3.7. Important dynamics of CeD market evolution

• Treatment-related unmet needs
• Figure 4.1. Top unmet needs in CeD
• Figure 4.2. Physician-reported unmet needs in CeD
• Physician commentary on unmet needs for novel CeD therapies

• Overview
• Figure 5.1. Number of emerging therapies whose primary clinical trial endpoint addresses unmet needs in CeD
• The pipeline for CeD is active with numerous treatments in Phase 2 clinical development
• Figure 5.2. Percentage of gastroenterologists rating emerging approaches as “promising”
• Table 5.1. Emerging clinical-stage therapies by target
• Gastroenterologists’ perspectives on emerging therapies
• The pipeline for CeD is active with numerous treatments in phase 2 clinical development

• Overview
• Figure 6.1. Reimbursement and access considerations for emerging therapies in CeD
• Figure 6.2. CeD patients by insurance type
• Key insights from the alopecia market
• Table 6.2. Payer coverage requirements of Olumiant to treat alopecia and relevance to CeD
• Improving patient access to new CeD medications will require strategic trial design and patient services
• Figure 6.3. Key considerations for driving access to and uptake of novel CeD therapies

• Primary market research approach
• Epidemiology methodology

Samples

Companies Mentioned

• Takeda Pharmaceuticals
• Anokion
• GlaxoSmithKline
• Immunic Therapeutics
• Provention Bio
• Amgen
• Calypso Biotech
• ImmunogenX
• Chugai Pharmaceutical